Mesenchymal Stem Cells

Recent research from the lab of Sandra Muntión (IBSAL‐Hospital Universitario de Salamanca, Salamanca, Spain) aimed to analyze changes induced in human CD34+ hematopoietic stem/progenitor cells following treatment with extracellular vesicles derived from mesenchymal stem cells (MSC-EVs).

New evidence suggests that repeated MSC application protects motor neurons and neuromuscular junctions by inhibiting major cell death pathways in ALS rats

Researchers use a rat model of diabetes to show how the autologous transplantation of MSC exosomes for bone regeneration may be unsuitable in some patients

Advanced clinical trials will require the definition of the immune potency of mesenchymal stem cell (MSCs) destined to be administered to human patients and to this end, researchers from the laboratories of Raghavan Chinnadurai and

A recent Perspectives article from the laboratory of Biju Parekkadan (Rutgers University, New Jersey, USA) discusses the development of an ex vivo mesenchymal stem cell (MSC) therapeutic adapting principles of classical molecular drug pharm

Trial of allogeneic MSC infusion before removal of the cancerous prostate establishes that cells do not home to primary tumor sites in sufficient levels

A new study supports chronic pancreatitis patient MSCs as autologous cell therapy in patients undergoing total pancreatectomy with islet transplantation

Metabolic syndrome may impair the therapeutic ability of mesenchymal stem cell-derived extracellular vesicles by promoting a proinflammatory EV profile

Macrophages educated to a proregenerative M2‐like state after exposure to MSC-derived extracellular vesicles promote regeneration in a mouse tendon rupture model

Research identifies hBM-MSC derived factors that promote islet regenerative and may permit the development of cell‐free therapies for diabetic patients